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Gene targeting with homologous recombination in embryonic stem cells created
a revolution in the analysis of the function of genes in behavioral brain research.
The technology allowed unprecedented precision with which one could manipulate
genes and study the effect of this manipulation on the central nervous system. With
gene targeting, the uncertainty inherent in psychopharmacology regarding whether a
particular compound would act only through a specific target was removed. Thus, gene
targeting became highly popular. However, with this popularity came the realization that
like other methods, gene targeting also suffered from some technical and principal
problems. For example, two decades ago, issues about compensatory changes and
about genetic linkage were raised. Since then, the technology developed, and its utility
has been better delineated. This review will discuss the pros and cons of the technique
along with these advancements from the perspective of the neuroscientist user. It
will also compare and contrast methods that may represent novel alternatives to the
homologous recombination based gene targeting approach, including the TALEN and
the CRISPR/Cas9 systems. The goal of the review is not to provide detailed recipes, but
to attempt to present a short summary of these approaches a behavioral geneticist or
neuroscientist may consider for the analysis of brain function and behavior.
Keywords: gene targeting, embryonic stem cell, homologous recombination, neuroscience, behavior genetics
INTRODUCTION
A simple search in PubMed using the key words “gene targeting” and “mice” returns close to
30,000 entries (Jan 2016). This is a vast literature, a number that shows the popularity and the
utility of this technology. Cross referencing the entries with the key word “brain”, reduces the
number of hits to about 4000, still a large number of papers just within the field of neuroscience. By
now, several thousand genes have been mutated using homologous recombination-based methods
in embryonic stem (ES) cells (Capecchi, 2005), and companies as well as major Governmental
funding agencies such as the National Institutes of Health of USA have made concerted efforts
to generate and assemble a collection of such mutant mouse lines (Austin et al., 2004). Also,
the International Mouse Knockout Consortium (IKMC) (http://www.knockoutmouse.org/) has
amassed a large collection of conditional knockout alleles for mouse genes, allowing neuroscientists
and other researchers to avoid having to go through the labor intensive process of generating
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null mutant mice. Undoubtedly, gene targeting with homologous
recombination in ES cells has revolutionarized the analysis
of gene function, and it had a major impact in biology that
was recognized by awarding the Nobel Prize in Physiology or
Medicine to the inventors who laid the foundation of the method,
Mario R. Capecchi, Sir Martin J. Evans, and Oliver Smithies
in 2007. The current review is not intended to capture the full
impact of this powerful method. Instead, it summarizes some
of the advantages as well as disadvantages of the methodology
as they pertain to behavioral and brain research. The review
provides a brief discussion of some of the principle and technical
challenges that the technology faced in the past, the solutions
that have been offered to address them, and the future of the
technology in the light of new developments in the field of gene
manipulation and genome engineering.
GENE TARGETING: GREAT PROMISE OF
SPECIFICITY
The late 1980’s witnessed the birth of an efficient method with
which investigators could silence their gene of choice. The
method was based upon homologous recombination between a
targeting vector and the endogenous gene of interest (Smithies
et al., 1985; Mansour et al., 1988; also see Capecchi, 2001). The
efficiency of the method was due to two main factors. One, the
selection for the appropriate gene targeting event was conducted
in the Petri dish, using ES cells instead of whole organisms.
Two, the selection included two main steps. The first step could
identify those ES cells whose genome contained the incorporated
targeting vector. This was achieved by engineering a neomycin
resistance conferring cassette into the homology region of the
targeting vector (usually in the region that would correspond to
an important and upstream exon of the targeted gene) (Cheah
and Behringer, 2000). The second step could identify those ES
cells in which the incorporation of the targeting vector happened
via homologous recombination, i.e., by replacing the endogenous
gene, as opposed to insertion into a random locus (Cheah and
Behringer, 2000). The latter step was achieved by inclusion
of the thymidine kinase cassette usually downstream of the
homology region of the construct (Mansour et al., 1988). This
double selection scheme thus allowed the investigator to quickly
and efficiently identify ES cells in which the gene of interest
was replaced by the targeting vector. Importantly, because
the targeting vector contained a non-native sequence, e.g., the
neomycin cassette, in the middle of an important exon of the gene
of interest, or had a stop codon upstream of coding regions, or
both, when this targeting vector replaced the endogenous gene,
there was either no protein expression from it, or the translated
protein was structurally so abnormal that it could not serve the
original biological function. Thus, the mutation induced with this
technology was called null mutation, and the transgenic mouse
carrying such a mutation, the knock out or null mutant mouse.
Knock out mice were an appealing tool for the neuroscientist,
and with the first two mouse knock out studies published from
the laboratories of two Nobel Laureates, Susumu Tonegawa
(Silva et al., 1992), and Eric Kandel (Grant et al., 1992) in
1992, the technology gained foothold in neurobiology. The main
appeal of these mice was that they possessed a genetically well
defined change, a single silenced gene with all other biological
targets (genes and gene products) intact. Or at least so was the
thinking of that era. The principal reason why gene targeting
was viewed as highly promising was that it offered an excellent
alternative to pharmacological methods. The latter suffered from
two fundamental problems. One, identification of compounds
that would interact with biological systems or targets required
large scale screening. The so called intelligent drug design, i.e.,
the ability to make custom designed small molecules that would
specifically bind biological targets of interest in a desired manner,
was not, and still is not, feasible. The second problem with
pharmacological tools was that even after the binding affinity
and efficacy of a particular small molecule have been confirmed,
the specificity of this compound remained in question. After
all, no one could tell for sure that a particular compound
would not bind or interact with a yet undiscovered molecular
target or biochemical pathway. Geneticists argued that for the
above reasons, gene targeting is the way to go. If the nucleotide
sequence of a gene was known, geneticists could custom design
a targeting vector that would specifically and selectively disrupt
the functioning of this, and only this target gene (Cheah and
Behringer, 2000). But as it turned out, this argument was not
entirely correct, at least not from the perspective of the main
reason why gene targeting would be conducted: the analysis of
the function of the gene, i.e., what role it may play in influencing
the phenotype.
FUNDAMENTAL AND TECHNICAL
ISSUES OF PAST GENE TARGETING
METHODS
There were two distinct problems with gene targeting, a technical,
and a more fundamental scientific issue. I deal with the latter
one first. The fundamental issue with gene targeting was what
became known as the problem of compensation. Investigators
occasionally noticed that despite clear and confirmed full
silencing of their target gene, i.e., despite a lack of functional gene
product, there was no observable phenotypical effect, as if the
gene had no function at all (Müller, 1999). The reason for the
latter, many argued, must have been compensation by “helper”
genes, as it has been empirically shown (Hummler et al., 1994).
The argument seemed reasonable given that we knew of many
gene families within which genes (most likely generated by DNA
sequence duplication events throughout evolution) would have
sisters, genes with highly similar nucleotide sequences encoding
proteins with highly similar, if not identical, functions. But
the phenomenon of compensation brought up another, rather
vexing issue. Some explained that the avalanche of compensatory
changes induced by the absence of a gene product may manifest
as secondary alterations at the phenotypical level that are
not truly directly related to the actual function of the target
gene (Gerlai, 1996b, 2000b). Let me illuminate the point with
a hypothetical example. Consider a simple gene family with
only two sister genes. Assume that these genes would express
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FIGURE 1 | The flanking allele (false positive finding) and the increased genetic variance (false negative finding) problems associated with the hybrid
origin of null mutant mice. For illustrative purposes, the figure focuses on the particular chromosome where the locus of the target gene is. (A) The genotype of
diploid ES cell derived tissue of the chimeric founder male (yellow indicating strain 129-type alleles, white segment indicating the null allele at the target gene locus)
and the genotype of the host female with which the chimeric male is mated (red indicating strain C57BL/6 type alleles). Note that if the testes of the male chimeric
founder mouse have developed from the ES cell (germ-line transmitting chimera), this male will produce strain 129 genotype sperm in which the chromosome with
the target gene locus will carry the null mutant allele with 50% probability. When a germ line transmitting male founder chrimera is crossed to a C57BL/6 female as
indicated in (A), individuals of the resulting F1 offspring generation (B) will be heterozygous for the strain 129-type versus strain C57BL/6 type alleles at all loci.
Notably, 50% of these mice will also be heterozygous for the null allele, while the other 50% will not carry the null allele, and will have one wild type allele from the
strain 129 genome and one wild type allele from the C57BL/6 genome at the locus of the target gene. (C) Shows the genotype of gametes (sperm or egg) of the F1
mice. During meiosis, recombination will shuffle the strain 129-type and C57BL/6 type alleles, resulting in recombinant chromosomes indicated by the yellow (strain
129-type) and red (strain C57BL/6-type) segments. In order to obtain homozygous null mutant mice, two F1 heterozygous null mutant individuals are mated
(indicated by the semicircle underneath the heterozygous null mutant F1). The genotype of F2 individuals (offspring from this F1 sibmating) thus can be described as
pairs of any chromosomes illustrated on (C). Note that the random recombination pattern induced genetic variance in this F2 segregating generation may make the
effect of the null mutation less detectable (leading to a false negative finding). Also note that chromosomes that carry the null allele (chromosomes a, b and c with the
white segment) have a strain 129-type region (yellow) surrounding the target gene locus, and that chromosomes that do not carry the null allele (chromosomes d, e
and f) have a C57BL/6-type region (red) surrounding the target gene locus. This pattern of recombination is simply due to that recombination occurs essentially
randomly, and to that the shorter the length of DNA the less likely that recombination occurs within that area. Thus, the closer one gets to the target locus that
carries the null mutation, the less likely a recombination event will be to occur, a phenomenon known in classical genetics as linkage. Therefore, because the
homologous recombination-based gene replacement event was achieved in the strain 129-type genome of the ES cell, the null allele will be surrounded by strain
129-type alleles, whereas the wild type allele of the target locus (which originates from the C57BL/6 genome) will be surrounded by C57BL/6 type alleles.
(D) Summarizes this, and illustrates that the closer one gets to the target locus carrying the null allele (chromosome g) the more likely one will find strain 129-type
alleles, whereas the closer one gets to the target locus carrying the wild type allele (chromosome h) the higher the probability will be for one to find C57BL/6 type
alleles. This problem has become known as the flanking allele or hitch-hiking gene issue. The flanking allele issue is problematic because the null mutant mice and
their wild type siblings differ in two ways: first, the former carries the null mutation while the latter does not; and second, the former has strain 129-type alleles around
the target locus while the latter has C57BL/6 type alleles around the target locus. Thus, one may falsely conclude that the phenotypical difference between null
mutant and wild type mice is due to the null mutation, when, in fact, it is the result of differences in alleles of genes whose loci reside in the, often large, flanking
region surrounding the target locus. Adapted from Gerlai (1996a).
proteins with highly similar amino acid sequence, and thus
protein function, but in a spatially slightly different expression
pattern. A real life example would be the EphA-family tyrosine
kinase receptors (Gerlai, 2001) (except that there are eight sister
receptors in this family). These receptors are highly similar, and
their spatial expression pattern is partially overlapping (Gerlai,
2001). Imagine we knocked out gene A1 and in response to this
null mutation gene A2 gets overexpressed. In the brain region
where both A1 and A2 would be expressed (the overlapping
area, say, area X) gene A2 would thus be able to compensate for
the absence of gene A1 product. However, note that the spatial
expression pattern of sister genes is almost never completely
overlapping. In the area where only gene A2 is expressed in the
wild type animal (say area Y), now gene A2 may be overexpressed
in the null mutant. This overexpression, may result in altered
functioning of this brain area and this alteration may be observed
at the level of behavior or any other phenotype. Thus, although
the experimenter may properly conclude that knocking out gene
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A1 alters the functioning of brain area Y, the argument that the
function of gene A1 is in area Y would be flawed.
The phenomenon of compensation, and the resulting
secondary changes, is a vexing issue (Gerlai, 1996b). It
undermines our ability to answer the question originally thought
of as the main goal of gene targeting: what is the function of the
gene in terms of its phenotypical effect. Compensation is a vexing
issue also because there really is no appropriate solution for it.
We can investigate the behavior of any system only when we
interact with it. Thus, we can never know how the intact system
would behave, i.e., how it was working before we interacted with
it, a problem inherent in all research, not just biology. Although
a complete solution to the above issue does not exist, one can
still limit the effect of compensation and the ensuing secondary
changes by restricting gene targeting temporally and/or spatially,
and thus making the genetic manipulation more specific and
controlled. This was achieved by the second generation gene
targeting methods (Mayford et al., 1997), to which I will return
later.
The second major problem with gene targeting, which was
pointed out already 20 years ago, concerns the hybrid origin of
the knock out mice (Gerlai, 1996a). This problem became known
in the literature as the flanking allele or hitchhiking gene issue.
The issue is a simple classical genetic phenomenon, linkage, but
one that was largely missed or ignored, and is still often ignored
in gene targeting studies (Figure 1). At the heart of the problem
lies our limitation of what type of ES cells may be available
for gene targeting. Briefly, the problem is as follows. Most ES
cells that have been developed for gene targeting purposes come
from substrains of mice called 129 (Nagy et al., 1993; Simpson
et al., 1997; Downing and Battey, 2004). It is not entirely clear
why strain 129 mice would allow the generation of ES cells
that are appropriate for the purposes of gene targeting (it may
be due to purely historical reasons, or perhaps to the unique
genetic make up of these strains). But the fact remains that
most currently available, and previously used, ES cells do come
from strain 129 mice (Papaioannou and Johnson, 1993). The
problem with this strain origin, especially for behavior or brain
researchers, however, is that strain 129 mice exhibit peculiar
phenotypical features. For example, these mice are extremely
passive, they do not perform well in several behavioral tasks
including certain learning paradigms (Crawley et al., 1997),
and they have numerous peculiar abnormalities in their brain,
including significantly diminished or completely absent corpus
callosum (Bohlen et al., 2012). For these reasons, behavioral
and brain scientists preferred using mice of other strains in
their studies. But because the ES cell in which the homologous
recombination event replacing the target gene occurred was
from the strain 129 mouse, they were forced to work with this
phenotypically abnormal animal. The simple solution seemed to
be to cross the ES cell derived germ line transmitting Chimera
(the male mouse in which the ES cell carrying the null mutation
gave rise to the testes and thus the sperm) to a female mouse
of the preferred strain origin, most often the C57BL/6 mouse to
create an F1 hybrid. While this cross did solve the phenotypical
issues, as the F1 hybrid did not exhibit the strain 129 specific
peculiarities, it brought about two main problems, which I will
discuss shortly. But first consider that the null mutation rarely
manifests in a heterozygous form, because the presence of the
null allele is usually fully compensated for by the presence
of the wild type allele on the sister chromosome in the F1
hybrid. Thus, in order to see the effect of the null mutation,
it often had to be in a homozygous form. To achieve this,
an F1 male and an F1 female had to be mated to generate
the F2 generation, in which 25% of the offspring carried the
null mutation in the homozygous form. This breeding scheme
(strain 129 ES cell carrying the mutation giving rise to the germ
line transmitting chimera, chimera crossed with C57BL/female,
F1 hybrid offspring mated with each other generating the F2)
became the gold standard of making stable homozygous null
mutant mouse lines. This breeding scheme generated two main
problems, one that led to false negative and the other to false
positive findings.
False negative findings arose because the F2 generation
was a genetically segregating generation in which genetic
variance was increased compared to the original parental
strains of the F1 generation. This was due to the fact that
individuals of this generation carried genetic recombinant
chromosomes, mixture of genes from two distinct strains,
the strain 129 type and the C57BL/6 strains. The problem
with increased genetic variance is that it makes detecting
null mutation effects more difficult. That is, compared to
within population variance, the difference between null and
wild type mice may be relatively small, leading to reduced
statistical power to find the difference, hence the false negative
finding.
The false positive finding aspect of the hybrid background,
however, is even more troublesome. It results from the fact
that the homologous recombination based gene replacement
event occurred on the strain 129 genetic background. When
strain 129 × C57BL/6 F1 hybrids are mated with each other,
during the meiotic cell division generating the gametes of these
mice, recombinant chromosomes are produced. According to
the basic principles of genetic recombination, the probability
of a recombination event to occur in a region of DNA is
proportional to the length of this DNA region. This means that
the closer we get to the targeted locus carrying the null allele,
the lower the probability of recombination and thus higher the
chance that we will find strain 129 type alleles, a phenomenon
known in classical genetics as linkage. Similarly, the closer we
get to the targeted locus carrying the wild type allele, the higher
the chance that we will find C57BL/6 alleles. Briefly, due to
genetic linkage the null allele may be viewed as a marker for
the strain 129 region and the wild type allele of that locus
may be viewed as a marker for C57BL/6 region of the given
chromosome.
What does this all mean in terms of the analysis of null mutant
mice, and why is this linkage issue a problem? It is a problem for
gene targeting studies because the homozygous null mutant mice
and the homozygous wild type control counterparts (littermates
in the very same F2 segregating generation) differ in two ways.
One, the null mutant mice carry the null allele and the wild
type mice do not, and two, the null mutant mice have strain 129
type alleles around the target locus, but the wild type mice have
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C57BL/6 alleles around the target locus. Briefly, the scientist who
is comparing null mutant and wild type mice can never decide
whether the phenotypical difference between these two groups
of animals is the result of the null mutation or of the genetic
difference in the regions flanking the target locus (Gerlai, 1996a).
This ambiguity may not represent a fundamental problem for
phenotypes where major gene effects leading to robust changes
are studied. However, for behavioral characteristics, including
mnemonic and cognitive features, emotional or personality traits,
and for many other neuroscience and also other subtle biology
related phenotypes expected or known to be influenced by a
large number of genes, the flanking allele problem questioned
the validity of the interpretation of gene targeting results, and
thus became a major issue in neuroscience studies (Gerlai,
1996a, 2000a). Notably, since the theoretical possibility of the
flanking allele issue was raised in 1996, empirical evidence has
been obtained multiple times that suggests the issue is real. For
example, most recently Vanden Berghe et al. (2015) exemplified
the phenotypic effects of 129-derived passenger mutations with
several case studies, and these authors also developed a web
tool to estimate the number and possible effect of the hitch-
hiking genes in transgenic mice. Others also demonstrated
background genotype dependent null mutation effects (Kõks
et al., 2009) and experimentally showed the importance of the
flanking region problem in null mutant mice, the “congenic
footprint”, even after several backcross generations (Schalkwyk
et al., 2007).
One may argue that second generation gene targeting, i.e.,
approaches in which inducible or cell type restricted gene
targeting is achieved, provides proper answer to the flanking
allele issue. For example, the ability to temporally control gene
expression in transgenic mice with the use of the tetracycline
transactivator or the reverse tetracycline transactivator systems
(Mansuy et al., 1998), allows one to conduct a within subject
comparison, i.e., comparison of “before and after” mutation
phenotypes of the particular subject. Similarly, restricting the
genetic manipulation to particular tissues, e.g., to particular
brain regions using the CRE-recombinase/LoxP system (e.g.,
Tsien, 2016) or a conceptually identical Flp recombinase/FRT
system (Andrews et al., 1985; Dymecki, 1996) would allow
one to compare null mutant mice in which different brain
areas are affected. Thus, one could argue that the flanking
allele effects in these null mutant mice should be the same,
and any differences among or between them must be the
result of the differential brain region dependent null mutation
effects. The problem with all of these arguments, however, is
that they assume the effects of the null mutation and of the
flanking alleles are additive. However, the assumption of lack
of interaction between such genetic effects is almost certainly
wrong.
And this is where we were about 15–20 years ago. What
has changed? Have gene targeting studies altered their methods
to address the above? How can the above problems be
addressed anyway? I will briefly discuss these questions in the
following pages, and subsequently will evaluate the homologous
recombination in ES cell-based gene targeting technology in the
light of more recent alternative methods.
SOLUTIONS FOR THE FLANKING
ALLELE PROBLEM
Since the gene targeting debate in 1996 (Crawley, 1996; Crusio,
1996; Gerlai, 1996a,b; Lathe, 1996), several solutions have been
offered for the flanking allele problem. In fact, an entire
conference was organized to discuss and address this problem
(Banbury Conference, 1997). However, admittedly, most of the
recommendations were able to address the issues only partially.
The simplest, and most often employed, “solution” is to backcross
the heterozygous null mutant to the preferred strain, most often
the C57BL/6 mouse. Backcrossing for 10 generations, for example
(well over a year long effort) would eliminate most of the strain
129 alleles making the resulting backcross animal’s genome 99%
C57BL/6 type. Even better, the elimination of strain 129 type
alleles may be accelerated if one tests for genetic markers and
selects the most C57BL/6 like individuals for breeding at every
generation of the backcross, a technique that became known as
speed congenics (Wong, 2002). The problem with this approach,
however, is that the closer one gets to the target locus, i.e., the
shorter the DNA region is around the targeted gene, the more
difficult (less probable) it will be to find a recombination event,
i.e., to exchange strain 129-type alleles with C57BL/6 type alleles
via random recombination. Briefly, to fully eliminate the possible
contribution of strain 129-type flanking alleles to the phenotype
of null mutant mice, one would need to backcross the mutants
for infinite number of times. Despite these limitations, numerous
gene targeting papers employed the backcross and glanced over
the possibility that the phenotype of the null mutant mouse may
still be influenced by 100s or perhaps thousands of flanking genes
around the target locus, a problem that continues to haunt gene
targeting studies even today.
Another solution, offered by Zimmer (1996), was to create a
control mouse population, using a breeding scheme identical to
that used for the generation of the null mutant mice. For example,
in addition to sibmating F1 heterozygous null mutants, in this
method one would also sibmate two wild type F1 individuals.
Since both the heterozygous null mutant and the wild type F1
mouse has one set of chromosomes from strain 129 and the
other from the C57BL/6 strain, the two F2 populations would,
on average, contain the same recombinant genetic patterns, i.e.,
the same genetic make up. The problem with this argument,
however, is again genetic linkage. By choosing the homozygous
null mutant mice from the F2 generation resulting from the
F1 heterozygous matings one is essentially selecting mice whose
target locus is surrounded by strain 129-type alleles. Whereas
breeding wild type F1 mice that carry no null mutation will result
in F2 generation mice whose targeted locus is not surrounded
by strain 129-type alleles more than at random chance, which
leads to a similar flanking allele issue to when one compares the
wild type and null mutant mice form the same segregating F2
generation.
The third solution offered was what we call a rescue
experiment. If one replaces the missing protein, via systemic
delivery, or via adding a normally functioning transgene
producing the endogenous gene product, and if this
manipulation reverses (rescues) the phenotypical changes seen
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in the null mutant mice, one has proven that the phenotypical
changes were indeed due to the null mutation. However, this
extra (and quite labor intensive) step, i.e., the rescue experiment,
is almost never attempted because the failure rate is expected to
be quite high especially compared to the efforts required.
The second generation gene targeting methods, i.e., those
that utilize temporally controllable and/or cell type restricted
silencing of target genes (see e.g., current special topic paper
on the CRE recombinase system by Tsien, 2016) have gained
increasing use in behavior and brain studies. These approaches
do offer the ability to create internal controls as explained above,
and thus were argued to address both the flanking allele and
the compensatory responses problems (Mayford et al., 1997).
The issue with many of these studies, however, again relates
to the hybrid origin of the mice used. For example, in case
of the Cre-lox system, one needs to generate a transgenic line
in which the Cre recombinase encoding transgene is driven by
a desired promoter, for example, the CamKII promoter, which
directs expression mainly to the forebrain and largely after
birth of the mouse. This transgenic animal must be crossed to
another transgenic mouse, in which the endogenous gene has
been replaced (using homologous recombination in ES cells) by a
construct that contains the entire target gene flanked by lox p site
sequences, the recognition sequences for the Cre recombinase.
Once this “floxed” gene is in the same genome as the CamKII-
Cre construct, the Cre will excise the floxed target gene, resulting
in complete silencing of the target gene only in tissues where and
when the CamKII promoter directed the expression of Cre (hence
the cell type specificity). This elegant technique, which has gained
widespread use (see current review in this special topic by Tsien,
2016), however, may still suffer from the same, or perhaps even
more complicated genetic background (hybrid origin) problem
as null mutant mice generated by classical, first generation, gene
targeting. This is because the line containing the floxed gene is
generated the same way as standard knock out mice, and thus has
the strain 129 vs. C57BL/6 background issue, and two, because
the transgenic line carrying the Cre construct is often of yet
another strain origin.
Perhaps the only true solution to the flanking allele and
also to the false negative problems is to completely eliminate
the hybrid origin of the knock out mouse. By using an ES
cell line that originates from the same mouse strain to which
the germ-line transmitting mutant chimera is crossed, one
generates null mutant mice that are on a pure bred, genetically
homogeneous, background. Although relatively rare, ES cells
of strains other than 129 substrains have been successfully
generated. For example, ES cells have been developed from inbred
mouse strains most often utilized in neurobehavioral genetic
research, which include C57BL/6 ES cell lines (Tanimoto et al.,
2008), BALB/c ES cells (NobenTrauth et al., 1996), and DBA
strain derived ES cells (Roach et al., 1995). These alternative
ES cells often require different maintenance protocols and/or
may not populate the founder chimera as efficiently as strain
129 derived ES cells (Ledermann, 2000), but they save all the
ambiguities associated with the traditional ES cell lines.
Last, another major limitation of the above discussed gene
targeting methods is that they are species specific. They have been
developed for the house mouse and cannot be easily adopted
for other species. The main limitation is the lack of availability
of ES cells, which are crucial for the efficient screening of the
appropriate gene targeting event. Recently, however, ES cells have
been developed for the rat, and thus transgenic and null mutant
rats have started to be utilized in brain research (Kawaharada
et al., 2015). This is a major step for biomedical neuroscience
research, because most traditional psychopharmacological and
toxicology studies have been conducted with this latter species.
Briefly, we know much more about the physiology, behavior and
neurobiology of the rat as compared to what we know about the
house mouse.
WILL HOMOLOGOUS
RECOMBINATION-BASED GENE
TARGETING SURVIVE THE TEST OF
TIMES?
The huge number of publications in which homologous
recombination in ES cells based gene targeting is utilized clearly
attests to the great utility and popularity of this technique.
Thus, perhaps the above critical comments may be too harsh.
Increasingly sophisticated ways of targeting genes in an inducible
(Mishina and Sakimura, 2007) and cell type restricted manner
(Mayford et al., 1997) also suggest that the method has a future.
New developments in the methods of how one can generate
genetically and/or epigenetically reprogrammed pluripotent cells
(Theunissen and Jaenisch, 2014) that can function as ES cells will
likely open the possibility of using gene targeting in numerous
species in addition to the traditional laboratory rodents. Even
the classical double selection method has been modified. For
example, an elegant auto-selection targeting vector has been
designed (Bouabe et al., 2011) in which the CRE recombinase
encoding sequence driven by a herpes simplex virus (HSV)
promoter was positioned outside the homology region of the
targeting vector, and the neomycin resistance gene cassette was
engineered with two loxP sites flanking it (floxed neo). In case
of random integration of this targeting vector, the CRE sequence
is expected to be incorporated into the genome. The resulting
expression of CRE recombinase excises the floxed neo and thus
such ES cells die in response to antibiotic treatment. However,
in case of homologous recombination, the CRE sequence is
expected to be lost, and the intact incorporated neo sequence is
expected to confer antibiotic resistance to such ES cells, hence the
ES cells are easily selectable for the homologous recombination
event with a single selection step, antibiotic application. Last,
but also notably, inducible gene expression systems and cell type
restricted conditional knock out may be combined to achieve
inducible AND cell type restricted conditional null mutation.
This system is essentially a CRE/loxP system in which CRE
expression is rendered inducible, i.e., temporally controllable.
For example, one can fuse a nucleotide sequence encoding the
mutated ligand-binding domain of the estrogen receptor (ER)
with the CRE sequence. Tamoxifen specifically binds this mutated
ligand-binding domain of the ER. In response to tamoxifen
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treatment, the CRE-ER fusion protein translocates from the
cytoplasm to the nucleus, where it can excise the loxP site flanking
target gene (Feil et al., 1996). A conceptually similar idea was
to combine the tetracycline transactivator system with the CRE
recombinase system. In this method, CRE expression is driven by
a minimal promoter with the tetracycline transactivator operator,
TetO, which may turn on CRE expression when tetracycline or
similar antibiotic analogs (e.g., doxicycline) are removed from the
diet or drinking water of the transgenic mouse (Shimizu et al.,
2000; Lindeberg et al., 2002).
Given such advances in gene targeting, the method originally
developed by the three pioneering Nobel Laureates, Capecchi,
Smithies and Evans, will likely withstand the test of times.
Nevertheless, it is also likely that in the future new recombinant
DNA methods, including the TALEN (transcription activator-
like effector nuclease) and the Clustered regularly interspaced
short palindromic repeats (CRISPR)/Cas9 (clustered regularly
interspaced short palindromic repeats) gene targeting systems
(Boettcher and McManus, 2015; Pu et al., 2015; also see current
special topic paper by Walters et al., 2016), will gain increasingly
strong roles in the genetic analysis of brain function and behavior.
One reason why these newly developed techniques may become
more frequently used at the expense of classical gene targeting is
that even though true-and-tried, the ES cell-based gene targeting
method is more time consuming, labor intensive and expensive
than many of the recently developed genome editing tools.
In addition, although not considered a gene targeting method
per se, optogenetics (which allow light controlled activation or
deactivation of particular neuronal circuits, Gross (2011)) and
promising combinations between pharmacology and genetics,
such as DREADDS (which utilizes genetically modified channels
or receptors designed to bind particular artificial ligands, Whissell
et al. (2016)), may also enrich the toolset of the neurobiologist
leading to unprecedented sophistication with which the central
nervous system may be probed. Some of these techniques are
discussed in this very issue/special topic (Lee et al., 2016; Walters
et al., 2016; Whissell et al., 2016), others have been reviewed and
explained in detail elsewhere. Thus, I only briefly discuss the
novel gene targeting systems, particularly in the context of how
they compare to classical gene targeting.
ALTERNATIVES OF HOMOLOGOUS
RECOMBINATION IN ES CELL-BASED
GENE TARGETING
Reverse genetics with the TALEN system has one major
advantage over homologous recombination in ES cell based gene
targeting. It can be conducted in any species. For example, while
classical gene targeting is currently restricted to the house mouse
and recently extended to the rat, the TALEN-based gene targeting
method is not dependent upon the availability of ES cells, and has
already been successfully utilized in a range of species, including,
for example, one of the simplest vertebrates, the zebrafish
(Clark et al., 2011; Lee et al., 2016). The method utilizes the
transcription activator-like effector proteins or TALEs, which are
site-specific DNA-binding proteins discovered in Xanthomonas
species, bacterial pathogens of plants. TALEs are simple proteins
consisting of 34 amino acids that recognize a specific DNA
base. Particular nucleotide sequence recognition is achieved by
building a series of TALEs (TALE repeats) specific to the target
sequence. Cutting of DNA at the specific target sequence is
accomplished by fusion of the catalytic domain of the FokI
endonuclease to the TALE repeats, a protein called transcription
activator-like effector nuclease or TALEN. Because the FokI
endonuclease requires dimerization in order for it to induce
double stranded cutting of DNA, two TALENs are designed, one
to recognize a nucleotide sequence on one side, say, 5′ to the cut
site, and another to recognize nucleotide sequence 5′ to the cut
side on the other strand of the DNA, with about a 15 base pair
gap in between these recognition sequences in the middle. Due
to DNA repair mechanisms, the double stranded cut is quickly
joined, but the repair is error prone often resulting in insertion
or deletion of nucleotides at the cutting site leading to frame
shift mutation, i.e., altered reading frame, which renders the
protein translated from this mutated gene functionally null. The
TALEN technology can also be used to insert short nucleotide
sequences at the cutting site using sequences that have a few
hundred base-pair long overlapping homologous sequences on
each side of the cut. Insertion of such sequences may be employed
to correct a mutant gene, to insert a sequence mimicking a
specific human mutation, and/or to insert reporter sequences,
for example encoding the green fluorescent protein, in addition
to disrupting a target gene. The latter not only allows efficient
generation of null mutations, but when the insertion is targeted
immediately downstream of the promoter of the gene of interest,
it allows one to map the expression pattern of the target gene.
Although fundamentally a reverse genetic technique, the
TALEN method may be utilized as a forward genetic approach
too. Given the relative ease with which a large number of
genes may be mutated, one can quickly generate a library of
mutants and screen for interesting mutation effects identifying
genes involved in particular functions. Furthermore, when
combined with the use of reporter constructs, one can focus the
phenotypical characterization to the most relevant mutants. For
example, in case of brain or behavioral research, the investigator
may ignore those mutants in which GFP expression driven by the
promoter of the mutated target gene is found in organs other than
the brain, a strategy successfully utilized in zebrafish, for example
(Clark et al., 2011). In summary, the TALEN technology is a
new, but rapidly evolving, genome engineering tool, which may
be employed in a flexible manner serving a variety of different
purposes in reverse as well as forward genetic studies conducted
with species not accessible for homologous recombination in ES
cell based gene targeting methods.
Nevertheless, as it employed now, the TALEN system has a
potential minor disadvantage over homologous recombination
based gene targeting: specificity. The number of TALE repeats
employed is usually not higher than 24, and thus the length
of recognition nucleotide sequence is quite short (also not
more than 24 nucleotides). Thus, the possibility of off-target
effects cannot be completely excluded. This is not a problem in
homologous recombination based methods where the homology
region of the targeting vector is much longer, as it often spans
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most, if not all, of the target gene. In fact, the importance of
nucleotide sequence homology is well illustrated by findings
showing that the most successful homologous recombination is
achieved when the targeting vector is generated from a genetic
background that is isogenic with the ES cell’s genome in which the
homologous recombination based gene replacement is supposed
to occur (te Riele et al., 1992).
The currently available CRISPR systems suffer more from the
problem of potential off-target effects compared to the TALEN
system, because the nucleotide sequence conferring specificity
is even shorter (not more than 20 nucleotides). Nevertheless,
the advantage of the CRISPR system over the TALEN method
is that it is comparably simpler to perform, and thus its
use is rapidly spreading across molecular biology laboratories.
Furthermore, similarly to the TALEN system, it allows genome
engineering in a variety of species. The CRISPR/Cas9 system
was developed for genome engineering after the discovery of a
defense mechanism that naturally occurs in bacteria (Doudna
and Charpentier, 2014). CRISPRs have been discovered in
the bacterial genome, and in between these short nucleotide
sequence repeats viral or plasmid DNA may integrate from
pathogens invading the bacterium (Fineran and Charpentier,
2012). The integrated foreign nucleotide sequence provides
a template for the transcription of a hybrid RNA molecule
(crRNA) that spans the incorporated foreign sequence from
the invading pathogen and sequences from the CRISPR repeats
flanking the foreign sequence. Following transcription, crRNA
hybridizes with a second RNA (the transactivating CRISPR RNA
or tracrRNA) and forms a complex with the Cas9 (CRISPR
associated protein 9) nuclease. Unlike restriction endonucleases,
Cas9 has no native preference for cutting at particular nucleotide
sequences. Its cutting specificity comes from the incorporated
foreign sequence flanked by the CRISPRs of the crRNA, which
allows Cas9 to create a double stranded break specifically at
the sequence of the pathogen’s DNA corresponding to the
incorporated sequence. Once this mechanism was understood,
it was quickly realized that this natural defense system may
be utilized for creating double stranded breaks at a sequence
of choice. In the CRISPR/Cas9 gene targeting system, the
crRNA and tracrRNA is fused into a single construct and this
guide RNA, or gRNA complexes with the Cas9 endonuclease
that now targets the specific sequence engineered into the
crRNA portion of the gRNA. The end result is a double
stranded break specifically at the 20 nucleotide long sequence
of choice. In other words, the cutting specificity of the Cas9
endonuclease has been made programmable (Doudna and
Charpentier, 2014). Non-homologous end-joining of DNA at
the double stranded break is highly error prone and often
leads to insertion or deletion of nucleotides leading to a shift
in the reading frame, which is expected to have a major
disruptive effect on the structure and thus the function of the
protein translated from this mutant gene. In addition, if a
donor DNA is added which has sequences that match those
that flank the site of the double stranded break, homology-
directed repair will lead to the incorporation of the donor
DNA. The latter thus allows the delivery of short nucleotide
sequences at a locus of choice, which, similarly to what may
be achieved with the TALEN technology, may allow one to
introduce specific mutations (e.g., mutation from a human
gene) or to repair mutations of the gene of interest. The
reason why the CRISPR/Cas9 technology is relatively simple
compared to other genome editing tools developed is that the
cutting specificity conferring nucleotide sequence (the gRNA)
is easy to design, and irrespective of its specific sequence it
always uses the same Cas9 endonuclease. Last, it is also notable
that recently, point mutated designer versions of Cas9 have
been created that are reported to increase specificity in cell
culture (Kleinstiver et al., 2016; Slaymaker et al., 2016). If
these pioneering efforts are successfully adapted to genetically
engineered animals, the enhanced Cas9 variants along with
improved software for designing sgRNAs may significantly
reduce the possibility of off-target effects associated with this
emerging technology.
Are these rapidly evolving novel genome engineering methods
always superior to homologous recombination in ES cells-based
gene targeting? Not necessarily. The latter still has utility for the
generation of conditional, cell type and temporally controlled
null mutations. Furthermore, if the human gene is complex,
large, and has multiple mutations, homologous recombination
in ES cells based gene targeting is still a method of choice
as it allows the knock in of the entire human gene, i.e.,
the generation of the genetic disease model in mice or rats.
However, the faster and more efficient reverse and forward
genetic methods including the TALEN and CRISPR/Cas9
systems will likely continue to gain increasing sophistication
and role in the analysis of brain function and behavior
and soon may take the lead in the laboratory of molecular
biologists.
In summary, the molecular neurobiologist of today has a
great selection of gene targeting methods available. Second
generation inducible and cell type restricted gene targeting
in ES cells continues to increase in terms of methodological
sophistication and thus remains one of the best techniques
for probing the brain. Nevertheless, new genome engineering
methods including the CRISPR/Cas9 and TALEN systems will
likely play increasingly important roles in the analysis of brain
function and behavior. These latter methods will not only make
gene targeting relatively easier and simpler to achieve, but they
will also extend genetic manipulation of brain function to a range
of species other than the traditional rodent laboratory research
organisms.
AUTHOR CONTRIBUTIONS
The author confirms being the sole contributor of this work and
approved it for publication.
FUNDING
RG was founded by NSERC and Brain Canada Foundation.
Frontiers in Genetics | www.frontiersin.org 8 April 2016 | Volume 7 | Article 43
fgene-07-00043 April 7, 2016 Time: 13:36 # 9
Gerlai Gene Targeting in Neuroscience
REFERENCES
Andrews, B. J., Proteau, G. A., Beatty, L. G., and Sadowski, P. D. (1985). The FLP
recombinase of the 2 micron circle DNA of yeast: interaction with its target
sequences. Cell 40, 795–803. doi: 10.1016/0092-8674(85)90339-3
Austin, C. P., Battey, J. F., Bradley, A., Bucan, M., Capecchi, M., Collins, F. S.,
et al. (2004). The knockout mouse project. Nat. Genet. 36, 921–924. doi:
10.1038/ng0904-921
Banbury Conference (1997). Mutant mice and neuroscience: recommendations
concerning genetic background. Neuron 19, 755–759.
Boettcher, M., and McManus, M. T. (2015). Choosing the right tool
for the job: RNAi, TALEN, or CRISPR. Mol. Cell. 58, 575–585. doi:
10.1016/j.molcel.2015.04.028
Bohlen, M. O., Bailoo, J. D., Jordan, R. L., and Wahlsten, D. (2012). Hippocampal
commissure defects in crosses of four inbred mouse strains with absent
corpus callosum. Genes Brain Behav. 11, 757–766. doi: 10.1111/j.1601-
183X.2012.00802.x
Bouabe, H., Moser, M., and Heesemann, J. (2011). Enhanced selection for
homologous-recombinant embryonic stem cell clones by Cre recombinase-
mediated deletion of the positive selection marker. Transgenic Res. 21, 227–229.
doi: 10.1007/s11248-011-9522-x
Capecchi, M. R. (2001). Generating mice with targeted mutations. Nat. Med. 7,
1086–1090. doi: 10.1038/nm1001-1086
Capecchi, M. R. (2005). Gene targeting in mice: functional analysis of the
mammalian genome for the twenty-first century. Nat. Rev. Genet. 6, 507–512.
doi: 10.1038/nrg1619
Cheah, S. S., and Behringer, R. R. (2000). Gene-targeting strategies. Methods Mol.
Biol. 136, 455–463. doi: 10.1385/1-59259-065-9:455
Clark, K. J., Voytas, D. F., and Ekker, S. C. (2011). A TALE of two nucleases: gene
targeting for the masses? Zebrafish 8, 147–149. doi: 10.1089/zeb.2011.9993
Crawley, J. N. (1996). Unusual behavioral phenotypes of inbred mouse strains.
Trends Neurosci. 19, 181–182 doi: 10.1016/S0166-2236(96)20021-9
Crawley, J. N., Belknap, J. K., Collins, A., Crabbe, J. C., Frankel, W., Henderson, N.,
et al. (1997). Behavioral phenotypes of inbred mouse strains: implications
and recommendations for molecular studies. Psychopharmacology (Berl). 132,
107–124. doi: 10.1007/s002130050327
Crusio, W. E. (1996). Gene-targeting studies: new methods, old problems. Trends
Neurosci. 19, 186–187. doi: 10.1016/S0166-2236(96)20023-2
Doudna, J. A., and Charpentier, E. (2014). Genome editing. The new
frontier of genome engineering with CRISPR-Cas9. Science 346:1258096 doi:
10.1126/science.1258096
Downing, G. J., and Battey, J. F. Jr. (2004). Technical assessment of the first 20 years
of research using mouse embryonic stem cell lines. Stem Cells 22, 1168–1180.
doi: 10.1634/stemcells.2004-0101
Dymecki, S. M. (1996). Flp recombinase promotes site-specific DNA
recombination in embryonic stem cells and transgenic mice. Proc. Natl.
Acad. Sci. U.S.A. 93, 6191–6196. doi: 10.1073/pnas.93.12.6191
Feil, R., Brocard, J., Mascrez, B., LeMeur, M., Metzger, D., and Chambon, P.
(1996). Ligand-activated site-specific recombination in mice. Proc. Natl. Acad.
Sci. U.S.A. 93, 10887–10890. doi: 10.1073/pnas.93.20.10887
Fineran, P. C., and Charpentier, E. (2012). Memory of viral infections by CRISPR-
Cas adaptive immune systems: acquisition of new information. Virology 434,
202–209. doi: 10.1016/j.virol.2012.10.003
Gerlai, R. (1996a). Gene targeting studies of mammalian behavior: is it the
mutation or the background genotype? Trends Neurosci. 19, 177–181. doi:
10.1016/S0166-2236(96)20020-7
Gerlai, R. (1996b). Gene targeting in neuroscience: the systemic approach. Trends
Neurosci. 19, 188–189.
Gerlai, R. (2000a). Targeting genes and proteins in the analysis of learning
and memory: caveats and future directions. Rev. Neurosci. 11, 15–26. doi:
10.1515/REVNEURO.2000.11.1.15
Gerlai, R. (2000b). Protein targeting: altering receptor kinase function in the brain.
Trends. Neurosci. 23, 236–239. doi: 10.1016/S0166-2236(00)01559-9
Gerlai, R. (2001). Eph tyrosine kinase receptors and neural plasticity. Nat. Rev.
Neurosci. 2, 205–209. doi: 10.1038/35058582
Grant, S. G., O’Dell, T. J., Karl, K. A., Stein, P. L., Soriano, P., and
Kandel, E. R. (1992). Impaired long-term potentiation, spatial learning, and
hippocampal development in fyn mutant mice. Science 258, 1903–1910. doi:
10.1126/science.1361685
Gross, M. (2011). Shining new light on the brain. Curr. Biol. 21, R831–R833. doi:
10.1016/j.cub.2011.10.007
Hummler, E., Cole, T. J., Blendy, J. A., Ganss, R., Aguzzi, A., Schmid, W.,
et al. (1994). Targeted mutation of the CREB gene: compensation within the
CREB/ATF family of transcription factors. Proc. Natl. Acad. Sci. U.S.A. 91,
5647–5651. doi: 10.1073/pnas.91.12.5647
Kawaharada, K., Kawamata, M., and Ochiya, T. (2015). Rat embryonic stem cells
create new era in development of genetically manipulated rat models. World J.
Stem Cells 7, 1054–1063.
Kleinstiver, B. P., Pattanayak, V., Prew, M. S., Tsai, S. Q., Nguyen, N. T., Zheng, Z.,
et al. (2016). High-fidelity CRISPR–Cas9 nucleases with no detectable genome-
wide off-target effects. Nature 529, 490–495. doi: 10.1038/nature16526
Kõks, S., Soomets, U., Paya-Cano, J. L., Fernandes, C., Luuk, H., Plaas, M.,
et al. (2009). Wfs1 gene deletion causes growth retardation in mice and
interferes with the growth hormone pathway. Physiol. Genom. 37, 249–259. doi:
10.1152/physiolgenomics.90407.2008
Lathe, R. (1996). Mice, gene targeting and behaviour: more than just genetic
background. Trends Neurosci. 19, 183–186. doi: 10.1016/S0166-2236(96)
20022-0
Ledermann, B. (2000). Embryonic stem cells and gene targeting. Exp. Physiol. 85,
603–613. doi: 10.1111/j.1469-445X.2000.02105.x
Lee, H. B., Sundberg, B. N., Sigafoos, A. N., and Clark, K. J. (2016). Genome
engineering with TALE and CRISPR systems in neuroscience. Front. Genet.
7:47. doi: 10.3389/fgene.2016.00047
Lindeberg, J., Mattsson, R., and Ebendal, T. (2002). Timing the doxycycline yields
different patterns of genomic recombination in brain neurons with a new
inducible Cre transgene. J. Neurosci. Res. 68, 248–253. doi: 10.1002/jnr.10213
Mansour, S. L., Thomas, K. R., and Capecchi, M. R. (1988). Disruption of the
proto-oncogene int-2 in mouse embryo-derived stem cells: a general strategy
for targeting mutations to non-selectable genes. Nature 336, 348–352. doi:
10.1038/336348a0
Mansuy, I. M., Winder, D. G., Moallem, T. M., Osman, M., Mayford, M., Hawkins,
R. D., et al. (1998). Inducible and reversible gene expression with the rtTA
system for the study of memory. Neuron 21, 257–265. doi: 10.1016/S0896-
6273(00)80533-4
Mayford, M., Mansuy, I. M., Muller, R. U., and Kandel, E. R. (1997). Memory
and behavior: a second generation of genetically modified mice. Curr. Biol. 7,
R580–R589. doi: 10.1016/S0960-9822(06)00287-9
Mishina, M., and Sakimura, K. (2007). Conditional gene targeting on the
pure C57BL/6 genetic background. Neurosci. Res. 58, 105–112. doi:
10.1016/j.neures.2007.01.004
Müller, U. (1999). Ten years of gene targeting: targeted mouse mutants, from
vector design to phenotype analysis. Mech. Dev. 82, 3–21. doi: 10.1016/S0925-
4773(99)00021-0
Nagy, A., Rossant, J., Nagy, R., Abramow-Newerly, W., and Roder, J. C.
(1993). Derivation of completely cell culture-derived mice from early-passage
embryonic stem cells. Proc. Natl. Acad. Sci. U.S.A. 90, 8424–8428. doi:
10.1073/pnas.90.18.8424
NobenTrauth, N., Kohler, G., Burki, K., and Ledermann, B. (1996). Efficient
targeting of the IL_4 gene in a BALB/c embryonic stem cell line. Transgenic
Res. 5, 487–491. doi: 10.1007/BF01980214
Papaioannou, V., and Johnson, R. (1993). “Production of chimeras and genetically
defined offspring from targeted ES cells,” in Gene Targeting: A Practical
Approach, ed. A. L. Joyner (Oxford: IRL), 1–31.
Pu, J., Frescas, D., Zhang, B., and Feng, J. (2015). Utilization of TALEN and
CRISPR/Cas9 technologies for gene targeting and modification. Exp. Biol. Med.
240, 1065–1070. doi: 10.1177/1535370215584932
Roach, M., Stock, J. L., Byrum, R., Koller, B. H., and McNeish, J. D. (1995). A new
embryonic stem cell line from DBA/1lacJ mice allows genetic modification in
a murine model of human inflammation. Exp. Cell Res. 221, 520–525. doi:
10.1006/excr.1995.1403
Schalkwyk, L. C., Fernandes, C., Nash, M. W., Kurrikoff, K., Vasar, E., and
Kõks, S. (2007). Interpretation of knockout experiments: the congenic
footprint. Genes Brain Behav. 6, 299–303. doi: 10.1111/j.1601-183X.2007.
00304.x
Frontiers in Genetics | www.frontiersin.org 9 April 2016 | Volume 7 | Article 43
fgene-07-00043 April 7, 2016 Time: 13:36 # 10
Gerlai Gene Targeting in Neuroscience
Shimizu, E., Tang, Y. P., Rampon, C., and Tsien, J. Z. (2000). NMDA
receptor-dependent synaptic reinforcement as a crucial process for memory
consolidation. Science 290, 1170–1174. doi: 10.1126/science.290.5494.1170
Silva, A. J., Paylor, R., Wehner, J. M., and Tonegawa, S. (1992). Impaired spatial
learning in alpha-calcium-calmodulin kinase II mutant mice. Science 257,
206–211. doi: 10.1126/science.1321493
Simpson, E. M., Linder, C. C., Sargent, E. E., Davisson, M. T., Mobraaten, L. E., and
Sharp, J. J. (1997). Genetic variation among 129 substrains and its importance
for targeted mutagenesis in mice. Nat. Genet. 16, 19–27. doi: 10.1038/
ng0597-19
Slaymaker, I. M., Gao, L., Zetsche, B., Scott, D. A., Yan, W. X., and Zhang F. (2016).
Rationally engineered Cas9 nucleases with improved specificity. Science 351,
84–88 doi: 10.1126/science.aad5227
Smithies, O., Gregg, R. G., Boggs, S. S., Koralewski, M. A., and Kucherlapati,
R. S. (1985). Insertion of DNA sequences into the human chromosomal
beta-globin locus by homologous recombination. Nature 317, 230–234. doi:
10.1038/317230a0
Tanimoto, Y., Iijima, S., Hasegawa, Y., Suzuki, Y., Daitoku, Y., Mizuno, S., et al.
(2008). Embryonic stem cells derived from C57BL/6J and C57BL/6N mice.
Comp. Med. 58, 347–352.
te Riele, H., Maandag, E. R., and Berns, A. (1992). Highly efficient gene
targeting in embryonic stem cells through homologous recombination with
isogenic DNA constructs. Proc. Natl. Acad. Sci. U.S.A. 89, 5128–5132. doi:
10.1073/pnas.89.11.5128
Theunissen, T. W., and Jaenisch, R. (2014). Molecular control of induced
pluripotency. Cell Stem Cell 14, 720–734. doi: 10.1016/j.stem.2014.05.002
Tsien, J. (2016). Cre-lox neurogenetics: 20 years of versatile applications in brain
research and counting. Front. Genet. 7:19. doi: 10.3389/fgene.2016.00019
Vanden Berghe, T., Hulpiau, P., Martens, L., Vandenbroucke, R. E., Van
Wonterghem, E., Perry, S. W., et al. (2015). Passenger mutations confound
interpretation of all genetically modified congenic mice. Immunity 43, 200–209.
doi: 10.1016/j.immuni.2015.06.011
Walters, B. J., Azam, A. B., Gillon, C. J., Josselyn, S. A., and Zovkic, I. B. (2016).
Advanced in vivo use of crispr/cas9 and anti-sense dna inhibition for gene
manipulation in the brain. Front. Genet. 6:362. doi: 10.3389/fgene.2015.00362
Whissell, P. D., Tohyama, S., and Martin, L. J. (2016). DREADDing behavior: The
Use of Chemogenetics to Deconstruct Neural Circuits. Front. Genet. (in press).
Wong, G. T. (2002). Speed congenics: applications for transgenic and knock-out
mouse strains. Neuropeptides 36, 230–236. doi: 10.1054/npep.2002.0905
Zimmer, A. (1996). Gene targeting and behaviour: a genetic problem requires a
genetic solution. Trends Neurosci. 19:470. doi: 10.1016/S0166-2236(96)20053-0
Conflict of Interest Statement: The author declares that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2016 Gerlai. This is an open-access article distributed under the terms
of the Creative Commons Attribution License (CC BY). The use, distribution or
reproduction in other forums is permitted, provided the original author(s) or licensor
are credited and that the original publication in this journal is cited, in accordance
with accepted academic practice. No use, distribution or reproduction is permitted
which does not comply with these terms.
Frontiers in Genetics | www.frontiersin.org 10 April 2016 | Volume 7 | Article 43
